MedPath

Prospective Evaluation of Frailty in Patients with Head and Neck Tumors Before Curative Intended Therapy

Not Applicable
Recruiting
Conditions
Head and Neck Cancers
Registration Number
NCT06638216
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

In a prospective study the fragility of patients with head and neck tumors before the start of curative therapy will be assessed.

Primary objective: Fragility is assessed using the G8 questionnaire.

Secondary objectives include the assessment of quality of life and financial burden (EORTC-QLQ C30+ H\&N43), swallowing function, cardiopulmonary resilience (6-minute walk test) and the patient's wishes regarding a prehabilitation program. Epidemiological and disease-related data is also collected.

Detailed Description

In this prospective study patients with a tumor of the head and neck region, that are planned for Surgery or radiotherapy (chemotherapy) will be included. The probability of developing therapy-associated side effects is significantly increased if the patient is already in a limited general condition, also known as fragility, before the therapy. In addition, due to demographic change, the incidence of head and neck tumors will continue to increase, especially in patients of advanced age. Due to their age, other pre-existing conditions and infirmity, they are at a further increased risk of therapy-related side effects In order to improve the care of patients with head and neck tumors, we must first determine how many patients are affected by fragility. In addition, we want to determine influencing factors that are associated with fragility. These include, for example, difficulty swallowing and weight loss. Based on this data, we will then plan the implementation of an intervention study to establish a prehabilitation program.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Indication for curative therapy in the case of an initial diagnosis of head and neck tumor disease
  • Capacity to consent
  • At least 18 years of age
  • Sufficient knowledge of the German language
Exclusion Criteria
    • Lack of capacity to consent
  • Age <18 years
  • Severe impairment of walking ability that makes it impossible to perform the 6MWT safely

Contraindications for performing a 6MWT:

Absolute contraindications* for the procedure are

  • unstable angina pectoris
  • myocardial infarction in the past month.

Relative contraindications are

  • a resting heart rate > 120/min
  • systolic blood pressure > 180 mmHg
  • a diastolic blood pressure > 100 mmHg.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Frailtyonce prior to surgery or at beginning of radiation

Assessment via G8 (Geriatric Screening Tool) questionnaire consists of 8 questions. The score ranges from 0 (poor score) to 17 points (good score), and a score of 11 or lower indicated frailty, whereas a score between 12 and 14 equals pre-frail patients. Patients with a score above 14 are considert non-frail.

Secondary Outcome Measures
NameTimeMethod
EORTC-QLQ C30 questionnaireprior to surgery or at beginning of radiotherapy

EORTC-QLQ C30 questionnaire consist of 30 questions with a score range from 0 to 100. Higher scores represents better quality of life, low scores indicating lower quality of life.

swallowing functionprior to surgery or beginning of radiation

Questionnaire (M.D. Anderson Dysphagia Inventory), scores range from 20 (poor function) to 100 (high function)

Cardio-pulmonary resilienceprior to surgery or beginning of radiation

6-Minute Walk test

Epidemiologic Dataprior to surgery or beginning of radiation

Descriptive (e.g. income, alcohol use, smoking status), epidemiologic data is not scored

Information on current tumor diseaseprior to surgery or beginning of radiation

number of patients with T1/T2/T3/T4 Tumor Stage and N1/N2/N3 lymphonodal stage

EORTC-H&N43 questionnaireprior to surgery or at beginning of radiotherapy

EORTC-H\&N43 questionnaires. Scores are from 0 to 100. A high score indicates high level of symptamotology.

Trial Locations

Locations (1)

Charité University Medicine Berlin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath